Black Diamond Therapeutics (BDTX) Scheduled to Post Earnings on Thursday

Black Diamond Therapeutics (NASDAQ:BDTX) will release its earnings data on Thursday, March 7th.

Black Diamond Therapeutics Stock Up 0.5 %

NASDAQ:BDTX traded up $0.02 during trading hours on Wednesday, hitting $4.42. 229,843 shares of the stock were exchanged, compared to its average volume of 629,021. The company’s 50 day moving average is $3.73 and its two-hundred day moving average is $3.04. Black Diamond Therapeutics has a twelve month low of $1.22 and a twelve month high of $6.85. The company has a market capitalization of $228.20 million, a P/E ratio of -2.08 and a beta of 2.65.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Black Diamond Therapeutics in a report on Wednesday, November 22nd.

Institutional Trading of Black Diamond Therapeutics

A number of large investors have recently made changes to their positions in BDTX. Cubist Systematic Strategies LLC increased its holdings in Black Diamond Therapeutics by 25.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 15,804 shares of the company’s stock worth $39,000 after purchasing an additional 3,244 shares in the last quarter. Walleye Capital LLC bought a new position in Black Diamond Therapeutics during the 3rd quarter worth about $44,000. AQR Capital Management LLC increased its holdings in Black Diamond Therapeutics by 34.4% during the 2nd quarter. AQR Capital Management LLC now owns 18,663 shares of the company’s stock worth $46,000 after purchasing an additional 4,773 shares in the last quarter. Stifel Financial Corp bought a new position in Black Diamond Therapeutics during the 3rd quarter worth about $58,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Black Diamond Therapeutics during the 2nd quarter worth about $73,000.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial.